denatonium benzoate
Trade name: Bitrex
Denatonium, usually available as denatonium benzoate (trade names Bitrex) is the most bitter chemical compound known, with bitterness thresholds of 0.05 ppm for the benzoate and 0.01 ppm for the saccharide. Scientists at Macfarlan Smith, Ltd. of Edinburgh, Scotland discovered Bitrex during research on derivatives of the anesthetic lidocaine. The extremely bitter taste proved effective in reducing ingestion by humans and animals. Denatonium is commonly included in placebo medications used in clinical trials to match the bitter taste of certain medications. Denatonium activates bitter taste receptor, mainly, TAS2R4, TAS2R8, TAS2R10, TAS2R13 on many cell types and plays important roles in chemical release, ciliary beating and smooth muscle relaxation through intracellular Ca(2+)-dependent pathways. — NCATS
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2011 (NCT02759926)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
SMILES
CC[N+](CC)(CC(=O)NC1=C(C)C=CC=C1C)CC2=CC=CC=C2- Mol. weight
- 325.4678 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDenatonium ↗
- NCATS4IK22DF4OU ↗
- ChEMBLCHEMBL6067658 ↗
- ChEMBLCHEMBL1738972 ↗
- ChEMBLCHEMBL1371493 ↗
Also known as
- bitrex
- denatonium benzoate
- denatonium benzoate
- denatonium benzoate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06310200 | Phase 1 | Aug 1, 2024 | Wright State University |
| NCT06003829 | Phase 1 | Jul 31, 2023 | Pfizer |
| NCT03777787 | N/A | Jan 14, 2019 | Katholieke Universiteit Leuven |
| NCT03985865 | Phase 4 | Mar 2, 2017 | Katholieke Universiteit Leuven |
| NCT02759926 | N/A | Aug 1, 2011 | Katholieke Universiteit Leuven |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Katholieke Universiteit Leuven | Academic/Hospital | 3 | 3 | 2 | 2011 |
| Pfizer | For profit | 1 | 1 | 1 | 2023 |
| Wright State University | Academic/Hospital | 1 | 1 | 1 | 2024 |